Comparison
GHRP-2 vs. Octreotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
158861-67-7
83150-76-9
Molecular weight
817.93 g/mol
1019.24 g/mol
Half-life
0.5 h
1.7 h
Sequence
D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Mechanism of action
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
4
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2